Voyager Therapeutics stockholders elect three Class II directors at 2023 annual meeting

Voyager’s stockholders ratified the appointment of Ernst & Young LLP as Voyager’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 29,090,596 32,521 2,864 —

Voyager’s stockholders elected Steven Hyman, M.D., James A. Geraghty, and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, subject to his earlier death, resignation, or removal. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Steven Hyman, M.D. 20,552,674 167,846 8,405,461 James A. Geraghty 16,613,243 4,107,277 8,405,461 Alfred Sandrock, M.D., Ph.D. 20,551,414 169,106 8,405,461

Voyager’s stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager’s named executive officers. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 20,162,995 523,972 33,553 8,405,461